Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Investigate the Mass Balance of [14C]-Nanatinostat and to Evaluate the Relative Bioavailability of Nanatinostat in Patients With Selected Advanced Cancers

NCT06302140 is registered in ClinicalTrials.gov with Viracta Therapeutics, Inc. as lead sponsor.

NCT NCT06302140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06302140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Investigate the Mass Balance of [14C]-Nanatinostat and to Evaluate the Relative Bioavailability of Nanatinostat in Patients With Selected Advanced Cancers
Lead sponsor
Viracta Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2024
Completion date
January 15, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer